NCT05652894进行中（未招募）3 期
A Randomized Phase III Study of HX008 (a Humanized Monoclonal Antibody Against PD-1) Compared to Investigator's Choice Chemotherapy in the First-Line Treatment of Subjects With Microsatellite Instability-High (MSI-H)/Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD63 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2023年2月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 190
- 试验地点
- 63
- 主要终点
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC)
研究概览
简要总结
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the Informed Consent Form（ICF）, understand the study, be willing to follow and be able to complete all test procedures;
- •Male or female, age ≥ 18 years on the day of signing the informed consent form;
- •Histologically or cytologically confirmed adenocarcinoma of the colon or rectum, classified as Stage IV according to the AJCC (8th edition, 2017) TNM staging system for colorectal cancer;
- •Confirmed MSI-H/dMMR status by the central laboratory;
- •No prior systemic treatment for metastatic colorectal cancer; subjects received neoadjuvant/adjuvant therapy with disease progression should be completed > 6 months prior to the neoadjuvant/adjuvant therapy were enrolled.
- •Has at least one measurable extracranial lesion (Lesions with the longest diameter ≥ 10mm, or lymph nodes with a short diameter ≥ 15mm) according to Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST1.1), which has not been treated with local treatment(Lesions located in the area of previous radiation therapy can also optional if the progression is confirmed);
- •Eastern Cooperative Oncology Group (ECOG) of 0 or 1;
- •Estimated life expectancy of ≥12 weeks;
- •Adequate organ and hematopoietic function (no blood transfusion within 14 days prior to hematology tests, and no use of any hematopoietic growth factors or/and thrombopoietic agents within 7 days), based on the following laboratory tests (retesting is allowed only once during the screening period. If the retest results meet the inclusion criteria, the baseline values will be based on the retest results.):
- •Absolute neutrophil count (ANC)≥1.5×10^9/L
- •White blood cell count (WBC)≥3×10^9/L
- •Platelet count (PLT)≥100×10^9/ L
- •Hemoglobin (HGB)≥90 g/L
- •Serum creatinine (Scr) ≤1.5×ULN
- •Alanine aminotransferase (ALT) 、Aspartate aminotransferase (AST) ≤2.5× (upper limit of normal, ULN) . Patients with liver metastases require ALT and AST≤5×ULN,
- •TBIL≤1.5×ULN
- •International normalized ratio (INR) ≤ 2×ULN; or activated partial thromboplastin time (APTT)≤ 1.5×ULN;(except for patients on anticoagulant therapy);
- •Women of childbearing age must have a negative pregnancy test within 72 hours before the first dose of trial treatment. Reproductive men and women of childbearing age are willing to take adequate contraceptive measures (such as oral contraceptives, intrauterine contraceptives, sexual abstinence, or barrier contraceptives combined with spermicide) from signing the informed consent form to 12 months after the last administration of the trial drug;
- •Participants must have good compliance.
排除标准
- •Prior systemic treatment for metastatic colorectal cancer (subjects who received neoadjuvant/adjuvant therapy with disease progression should be completed > 6 months prior to the neoadjuvant/adjuvant therapy were enrolled.)
- •Subjects diagnosed with any other malignancy within 5 years prior to randomization, except for malignancies with a low risk of metastasis and death (5-year survival rate > 90%), such as adequately basal cell or squamous cell skin cancer or carcinoma in situ of the cervix and other carcinomas in situ;
- •Had prior treatment with any anti-PD-1, anti-PD-L1, PD-L2, or CTLA-4 agent or any other drug targeting T cell co-stimulation or immune checkpoint pathway;
- •Has active autoimmune disease (except for psoriasis), that has required systemic treatment in the past 2 years((eg, corticosteroids or immunosuppressive drugs). Except for alternative therapies (eg, thyroxine, insulin or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency);
- •Need to receive systemic corticosteroids (dose equivalent to > 10 mg prednisone/day) or other immunosuppressive drugs within 14 days before enrollment or during the study period. Those under the following conditions are eligible:
- •Locally external use or inhaled corticosteroids;
- •short-term (≤ 7 days) use of glucocorticoids for the prevention or treatment of nonautoimmune allergic diseases;
- •Has had prior radiation therapy or has not recovered (≤ Grade 1 or at Baseline) from Adverse events(AEs) due to a previous radiation therapy;
- •Has received a significant surgery, open biopsy, or severe trauma within 4 weeks prior to randomization; Definition of major surgery: the minimum of 3 weeks of post-operative recovery time is required to undergo this study, any wound-related AE must be resolved prior to randomization;
- •Has severe infection within 4 weeks or active infection requiring IV infusion or oral administration of antibiotics within 2 weeks prior to randomization;
- •Treatment with investigational products or devices from other clinical trials within 4 weeks prior to randomization;
- •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or found during screening;
- •Has uncontrolled ascites requiring repeated drainage, pleural effusion, or pericardial effusion;
- •Has incomplete intestinal obstruction, active gastrointestinal hemorrhage, or perforation;
- •Has a history or current interstitial pneumonia, or current non--infectious pneumonitis treatment with corticosteroids
- •Participants with inadequately controlled cardiovascular diseases judged by the investigator as unsuitable for participation in this trial, including but not limited to: (1) NYHA Class II or above cardiac function, (2) Angina unstable;
- •Subjects with active tuberculosis;
- •History of human immunodeficiency virus infection, acquired or congenital immunodeficiency disease, organ transplantation, or stem cell transplantation;
- •Active chronic hepatitis B or active hepatitis C. Except for hepatitis B virus carriers or those with stable disease after drug treatment, and participants with HBV DNA titer ≤ 500 IU/mL or < 2500 copies/mL are eligible. Active hepatitis C is defined as known positive hepatitis C antibody with known hepatitis C RNA quantitative results above the lower limit of detection of the analytical method;
- •Known to be allergic to macromolecular protein agents or monoclonal antibodies. Known to have a history of severe allergies to any of the chemotherapy drugs in the study ;
- •Alcohol dependence or drug abuse within the past 1 year;
- •Has received a live vaccine within 30 days prior to the first dose of trial treatment. Subjects are permitted to receive inactivated vaccines including those for seasonal influenza, intranasal influenza vaccines are not allowed;
- •Presence of other serious physical or mental illness or abnormal laboratory tests that may increase the risk of subjects in the study, or interfere with the study results, and the researchers believe that patients who are not suitable to participate in the trial for other reasons.
研究组 & 干预措施
Investigator's Choice Chemotherapy
Active Comparator
- mFOLFOX6
- mFOLFOX6+Bevacizumab
- mFOLFOX6+Cetuximab
- FOLFORI
- FOLFORI+Bevacizumab
- FOLFORI+Cetuximab
- CAPEOX
- CAPEOX+ Bevacizumab
干预措施: Investigator's Choice Chemotherapy (Drug)
HX008(Pucotenlimab)
Experimental
Subjects receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
干预措施: HX008(Pucotenlimab) (Drug)
结局指标
主要结局
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC)
时间窗: 2 years
PFS, defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by IRC or death due to any cause, whichever occurs first.
次要结局
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigators(2 years)
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators(2 years)
- Overall Survival (OS)(2 years)
- Immune Progression-free Survival (iPFS)-Experimental group per iRECIST assessed by IRC/investigators(2 years)
- Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators(2 years)
- Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators(2 years)
- Immune Objective Response Rate (iORR)-Experimental group per iRECIST assessed by IRC/investigators(2 years)
- Immune Disease Control Rate (iDCR) -Experimental group per iRECIST assessed by IRC/investigators(2 years)
- Immune Duration of Response (iDOR)-Experimental group per iRECIST assessed by IRC/investigators(2 years)
- Objective tumor response rate 2 (ORR2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators(2 years)
- Disease Control Rate 2 (DCR 2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators(2 years)
- Duration of Response 2 (DOR2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators(2 years)
- Progression-free Survival 2 (PFS2) (crossover phase) per Response Evaluation Criteria in Solid Tumors(2 years)
- Immune Objective Response Rate 2 (iORR2) (crossover phase) per iRECIST assessed by IRC/investigators(2 years)
- Immune Disease Control Rate 2 (iDCR2) (crossover phase) per iRECIST assessed by IRC/investigators(2 years)
- Immune Duration of Response 2 (iDOR2) (crossover phase) per iRECIST assessed by IRC/investigators(2 years)
- Immune Progression-free Survival 2 (iPFS2) (crossover phase) per iRECIST assessed by IRC/investigators(2 years)
- Adverse events(2 years)
- Safety: AEs, laboratory test parameters, etc.(2 years)
- Quality of life assessment(2 years)
- Objective tumor response rate 2 (ORR2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by investigators(2 years)
- Disease Control Rate 2 (DCR 2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by investigators(2 years)
- Duration of Response 2 (DOR2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by investigators(2 years)
- Progression-free Survival 2 (PFS2) per Response Evaluation Criteria in Solid Tumors(2 years)
- Immune Objective Response Rate 2 (iORR2) (crossover phase) per iRECIST assessed by investigators(2 years)
- Immune Disease Control Rate 2 (iDCR2) (crossover phase) per iRECIST assessed by investigators(2 years)
- Immune Duration of Response 2 (iDOR2) (crossover phase) per iRECIST assessed by investigators(2 years)
- Immune Progression-free Survival 2 (iPFS2) (crossover phase) per iRECIST assessed by investigators(2 years)
研究者
研究点 (63)
Loading locations...
相似试验
尚未招募
3 期
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the LiverMelanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms NeoplasmsNCT05647954Taizhou Hanzhong biomedical co. LTD350
已完成
3 期
Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster VaccinationNeisseria MeningitidisBacterial InfectionsVirus DiseasesNCT01839175Sanofi Pasteur, a Sanofi Company350
Unknown
2 期
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerNonsquamous Non-small Cell Lung CancerNCT04750083Taizhou Hanzhong biomedical co. LTD700
已完成
3 期
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria PatientsFalciparum MalariaNCT00403260Medicines for Malaria Venture1,271
招募中
2 期
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)Gastrointestinal Neuroendocrine Pancreatic TumorNCT06505395CSPC ZhongQi Pharmaceutical Technology Co., Ltd.90